* Spero Therapeutics Inc reported quarterly adjusted earnings of 96 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of 55 cents. The mean expectation of three analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -29 cents to 5 cents per share.
* Revenue rose 55% to $73.52 million from a year ago; analysts expected $18.63 million.
* Spero Therapeutics Inc's reported EPS for the quarter was 96 cents.
* The company reported quarterly net income of $51.19 million.
* Spero Therapeutics Inc shares had risen by 12.9% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 300% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Spero Therapeutics Inc is $7.50 This summary was machine generated from LSEG data March 14 at 03:42 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.10 0.96 Beat
Sep. 30 2023 -0.03 0.04 Beat
Jun. 30 2023 -0.34 -0.23 Beat
Mar. 31 2023 -0.33 -0.25 Beat
Comments